A 52-year-old postmenopausal woman presents with a 2-month history of a painless, hard lump in the upper outer quadrant of her left breast. On examination, the mass is 2 cm, fixed to the chest wall, with overlying skin dimpling. There is ipsilateral axillary lymphadenopathy. Mammography shows a dense, irregular mass with microcalcifications. Core needle biopsy confirms invasive ductal carcinoma (IDC). Immunohistochemistry shows ER+, PR+, HER2−. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has locally advanced breast cancer with a 2 cm mass **fixed to the chest wall**, overlying **skin dimpling**, and **ipsilateral axillary lymphadenopathy** — features consistent with at least Stage IIIA (T2N1M0 with chest wall fixation suggesting T4b, or T3N1). The tumor is ER+, PR+, HER2−. ## Why Neoadjuvant Chemotherapy is the Most Appropriate Next Step **Key Point:** According to current NCCN guidelines and standard oncology practice (referenced in Harrison's Principles of Internal Medicine, 21st ed.), **neoadjuvant (preoperative) chemotherapy** is the preferred initial approach for locally advanced breast cancer when the tumor is: - Fixed to the chest wall (T4 feature) - Associated with skin changes (dimpling/peau d'orange) - Accompanied by clinically positive axillary nodes Fixation to the chest wall is a hallmark of **T4 disease**, which renders the tumor **not immediately amenable to clear-margin resection** without prior downstaging. Neoadjuvant chemotherapy aims to: 1. Downstage the primary tumor to allow breast-conserving surgery or improve resectability 2. Eradicate micrometastatic disease early 3. Assess in-vivo chemosensitivity (pathologic complete response is a prognostic marker) 4. Convert axillary node-positive disease to node-negative in some cases ## Why the Other Options Are Incorrect - **Option A (HRT):** Hormone replacement therapy is absolutely contraindicated in ER+ breast cancer — it would stimulate tumor growth. - **Option C (Tamoxifen monotherapy without surgery):** Endocrine therapy alone is not curative intent management for a resectable/potentially resectable locally advanced cancer in a fit patient; surgery remains essential. - **Option D (Immediate MRM with ALND):** While MRM is ultimately part of the treatment plan, proceeding directly to surgery when the tumor is fixed to the chest wall risks positive margins and does not follow current guidelines. Neoadjuvant therapy first is the standard of care for T4/locally advanced disease. ## Post-Neoadjuvant Plan After neoadjuvant chemotherapy, the patient proceeds to: 1. **Surgery** — MRM or breast-conserving surgery depending on response 2. **Adjuvant endocrine therapy** — Aromatase inhibitor (postmenopausal) for 5–10 years 3. **Radiation therapy** — To chest wall and regional nodes 4. **CDK4/6 inhibitor consideration** if high residual risk **Clinical Pearl:** For ER+/HER2− locally advanced breast cancer with chest wall fixation, neoadjuvant chemotherapy (e.g., AC → paclitaxel) is the standard first step per NCCN guidelines. Neoadjuvant endocrine therapy is an alternative in frail patients but not the primary recommendation for fit patients with aggressive features. **High-Yield:** Chest wall fixation = T4b = locally advanced = neoadjuvant chemotherapy before surgery.